Twist Bioscience Corporation (TWST) Stock Analysis

Q: What is the TWST stock price target?

Take-profit $64.74 (+10.7% upside). Prior stop was $54.39.

Q: What are the risks of investing in TWST?

Concentration risk — Supplier: single-source supplier; Target reached (-18.2% upside); Quality below floor (3.0 < 4.0); Target reached (-18.2% upside); Quality below floor (3.0 < 4.0).

Q: Is TWST overvalued or undervalued?

Twist Bioscience Corporation trades at a P/E of N/A (forward -30.1). TrendMatrix value score: 3.5/10. Overall verdict: Sell.

Q: What do analysts say about TWST?

17 analysts cover TWST with a consensus score of 4.2/5. Average price target: $55.

SellVALUE-TRAP 2/5Moderate ConfidenceUpdated 2026-04-30

Healthcare · Diagnostics & Research

Earnings in 4 days (2026-05-04). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Twist Bioscience manufactures synthetic DNA using a proprietary silicon chip platform, serving synthetic biology, NGS tools, and biopharma antibody discovery markets. Revenue was $376.6M in fiscal 2025 from 3,800+ customers across healthcare, chemicals/materials, and academic... Read more

$58.62+10.7% A.UpsideScore 4.1/10#25 of 25 Diagnostics & Research

Stop $54.39Target $64.74(resistance)A.R:R -1.2:1

Analyst target$55.00-6.2%9 analysts

$64.74our TP

$58.62price

$55.00mean

$36

$75

Sell if holding. Engine safety override at $58.62: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10. Specifically: High short interest: 31%; Elevated put/call ratio: 9.95; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.1/10, moderate confidence.

Passes 4/7 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 4d<=7d. Suitability: aggressive.

Thesis

Rewards

No bull case signals

Risks

Concentration risk — Supplier: single-source supplier

Target reached (-18.2% upside)

Quality below floor (3.0 < 4.0)

Key Metrics

P/E (TTM)—

P/E (Fwd)-30.1

Mkt Cap$3.5B

EV/EBITDA-30.1

Profit Mgn-19.6%

ROE-16.8%

Rev Growth16.9%

Beta2.21

DividendNone

Rating analysts17

Quality Signals

Piotroski F6/9

Options Flow

P/C9.95bearish

IV109%elevated

Max Pain$35-40.3% vs spot

Concentration Risks(10-K Item 1A)

HIGHSuppliersingle-source supplier
10-K Item 1A: 'We depend on one single-source supplier for a critical component for our DNA synthesis process.'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

5 floor-breakers

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value3.515%0.53

Quality3.015%0.45

Growth6.715%1.00

Momentum3.010%0.30

Sentiment5.910%0.59

Insider Activity3.310%0.33

Peer Rank2.510%0.25

Technical Setup5.15%0.26

Risk Profile1.95%0.10

Catalyst5.25%0.26

Overall (Σ contributions)4.06

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Volatile — 6.5% daily ATR makes tight stops impractical. Position-size conservatively.static

Days To Cover

0.0

Volatility

0.0

Put Call

0.0

Implied Vol

0.0

Short Interest

0.4

Beta

2.6

Max Pain Risk

3.0

Debt Equity

9.0

High short interest justified: 31%Elevated put/call: 9.95High IV: 109%Above max pain $35Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank

0.2

Value Rank

2.4

Growth Rank

7.2

Unprofitable operations — net margin -19.6%. Quality floor flags this regardless of sector context.static

Roe

0.0

Roa

0.0

Operating Margin

0.0

Net Margin

0.0

Fcf Quality

0.0

Moat

5.0

Gross Margin

6.3

Piotroski F

6.7

Current Ratio

9.2

Cash-burning: FCF -12% of revenueNo competitive moat

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd

0.0

Volume

0.0

Obv

1.0

Rsi

5.0

Ma Position

9.0

Volume distribution (falling OBV)Above 200-day MA

Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static

Analyst Target

3.0

4.2

Low model confidence on this dimension (33%).

GatesMomentum 3.0<4.5A.R:R -1.2=NEGATIVEEARNINGS PROXIMITY 4d<=7dInsider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARSuitability: Aggressive

RSI

67 · Neutral

↑ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $46.56Resistance $66.06

Price Targets

$54

$65

A.Upside+10.4%

A.R:R-1.2:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Target reached (-18.2% upside)

! Quality below floor (3.0 < 4.0)

! Value-trap signals (2/5): Margin compression (op margin -9.4%), Material insider selling (9 sells, 0.05% of cap)

Earnings

3/4 beats

Next Earnings2026-05-04 (4d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is TWST stock a buy right now?

Sell if holding. Engine safety override at $58.62: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10. Specifically: High short interest: 31%; Elevated put/call ratio: 9.95; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $54.39. Score 4.1/10, moderate confidence.

What is the TWST stock price target?

Take-profit target: $64.74 (+10.7% upside). Prior stop was $54.39. Stop-loss: $54.39.

What are the risks of investing in TWST?

Concentration risk — Supplier: single-source supplier; Target reached (-18.2% upside); Quality below floor (3.0 < 4.0).

Is TWST overvalued or undervalued?

Twist Bioscience Corporation trades at a P/E of N/A (forward -30.1). TrendMatrix value score: 3.5/10. Verdict: Sell.

What do analysts say about TWST?

17 analysts cover TWST with a consensus score of 4.2/5. Average price target: $55.

What does Twist Bioscience Corporation do?Twist Bioscience manufactures synthetic DNA using a proprietary silicon chip platform, serving synthetic biology, NGS...